Cite
MLA Citation
D Kudrow et al.. “P.032 Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial.” Canadian journal of neurological sciences, vol. 48, n.d., p. S29. http://access.bl.uk/ark:/81055/vdc_100148164997.0x00003a